Human IL-6R (CD126) Antibody - Tocilizumab Biosimilar

Human IgG1 monoclonal antibody (mAb) against human IL-6R

InvivoGen provides Anti-hIL-6R-hIgG1, the biosimilar of the clinical antibody tocilizumab.
It features:

• the variable region of tocilizumab targeting the human interleukin 6 receptor (IL-6R)
• the IgG1 constant region of tocilizumab mediating high effector functions

InvivoGen's Anti-hIL6R-hIgG1 was generated by recombinant DNA technology, produced in Chinese hamster ovary (CHO) cells, and purified by affinity chromatography. Each lot is functionally tested by flow cytometry and cellular assays (see figures).
 

Key features of the Anti-hIL6R-hIgG1

• Clinically-relevant variable region targeting human IL-6R (Tocilizumab)
• Human IgG1 constant region for high effector functions
• Inhibition of IL-6-dependent signaling has been validated in HEK-Blue™ IL-6 cellular assays
• The absence of bacterial contamination has been confirmed
   

IL-6R background

Tocilizumab (TCZ) is a recombinant, humanized monoclonal antibody (mAb) directed against both soluble and membrane-bound human IL-6R. TCZ exhibits anti-inflammatory activity by inhibiting the binding of the pro-inflammatory cytokine, IL-6  to its receptor [1]. IL-6 exerts its biological effects through IL-6R, and the transmembrane protein gp130. Despite only a few cells expressing IL-6R on their surface, many cells respond to IL-6 due to the existence of soluble IL-6R [2]. TCZ can block both modes of signaling [1]. TCZ has been approved for the treatment of inflammatory diseases and conditions such as rheumatoid arthritis (RA) and cytokine release syndrome (CRS), a side effect of CAR-T therapy. Furthermore, it is under investigation for the treatment of the late-stage hyperinflammation observed in severe COVID‑19 patients [3].

References:

1. Sheppard, M. et al. 2017. Tocilizumab (Actemra). Hum Vaccin Immunother 13, 1972- 1988.
2. Rose-John, S. 2012. IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6. Int J Biol Sci 8, 1237-1247.
3. Zhang, S. et al. 2020. Rational Use of Tocilizumab in the Treatment of Novel Coronavirus Pneumonia. Clin Drug Investig.